The Law That Tried to Move the Factories Back

On Monday 8 June 2026, a document appeared on a Pentagon media server. It was a list, formally titled Entities Identified as Chinese Military Companies Operating in the United States, and the version posted that day was longer than the last one by several dozen names 4. Most of them were electronics, batteries, drones, internet platforms. One was a contract manufacturer whose chemistry plants make a large share of the world's outsourced drug ingredients, including a fast-growing volume of peptides. By lunchtime in New York, procurement teams at American biotech companies were re-reading a law that had been signed six months earlier and that most of them had been hoping would stay theoretical. That law is the BIOSECURE Act. It does not ban anyone from making or buying peptides. It bars United States federal agencies from buying biotechnology equipment or services from designated companies, and from contracting with businesses that use them to perform federal work — a narrow lever that has nonetheless set the industry's supply chains moving.

This site has told the story of how peptide manufacturing moved east — the solvent, the waste, the contract plants selling capacity by the kilogram — and of the shortage years that exposed how thin parts of the chain had become. This is the counter-current: the first serious legal attempt to pull some of that work back, what it actually says, and what it does not.

A bill that became a section

The BIOSECURE Act spent most of 2024 as a standalone bill that named specific Chinese companies in its text, and it stalled. What passed in December 2025 is a reworked version folded into the annual defence authorisation, the must-pass legislation that funds the United States military. The National Defense Authorization Act for Fiscal Year 2026 cleared Congress in mid-December and was signed on 18 December as Public Law 119-60 1. The BIOSECURE provisions sit in Section 851, titled Prohibition on Contracting with Certain Biotechnology Providers 2.

The enacted text names no companies. Instead it defines a category, the biotechnology company of concern, and gives two routes into it. The first is automatic: an entity that appears on the Department of Defense's 1260H list and is involved in biotechnology equipment or services. The second is a criteria-based process in which the Office of Management and Budget, with other agencies, designates companies judged to be controlled by, or to pose a national-security risk through their connection to, a foreign adversary government 23.

What it restricts

The operative prohibitions are about the federal government's own money. Once in force, executive agencies may not procure biotechnology equipment or services from a biotechnology company of concern; may not enter into, extend or renew contracts with entities that use such equipment or services in performing a federal contract; and may not obligate grant or loan funds for those purposes 23. The knowledge standard is actual knowledge — a contractor is caught where it knows its federal work will rely on a designated company, a narrower test than earlier drafts proposed 3.

That reach is wider than it first sounds. Very large parts of the American life-sciences economy touch federal money somewhere: government contracts, research grants, defence and public-health programmes. A drug developer with no federal contract today may want one tomorrow, or may be acquired by a company that has one. The practical effect of the statute is therefore to make a designated supplier a liability in any business plan that might one day meet a federal agency.

What it does not restrict

Equally important is what the section leaves alone. It applies to federal contracting, not to private transactions: a private company paying a designated manufacturer with its own money, for work unconnected to a federal contract, is not prohibited from doing so 2. It is not an import ban and not a sanctions regime. It explicitly preserves reimbursement eligibility under Medicare Part B and Medicaid 3. It excludes certain healthcare services and medical countermeasures in emergencies, and allows agencies to grant time-limited, case-by-case waivers 2.

It also does not act quickly. The Office of Management and Budget has one year from enactment — to December 2026 — to publish its list of biotechnology companies of concern. Guidance follows within 180 days of that list, the Federal Acquisition Regulation is then revised within a year of the guidance, and the prohibitions take effect 60 days after that revision for 1260H-listed companies and 90 days after it for the others. Contracts entered into before the effective date, including previously negotiated options, are protected for five years from the procurement-rule change 23. On the lawyers' own projections, the prohibitions bite in 2028 and the grandfathered contracts run into the 2030s 3.

The list, and the lawsuit

The 1260H list predates BIOSECURE. It comes from the defence authorisation for fiscal year 2021, which required the Pentagon to publish the names of companies it considers Chinese military companies operating in the United States. For years the list was mainly reputational. It is still not a sanctions list, but separate legislation has given it teeth of its own: from 30 June 2026 the Department of Defense may not enter into, renew or extend contracts with listed entities, and from 30 June 2027 it may not buy goods or services produced by them 5.

The June 2026 update added 65 entities, including new parent companies and subsidiaries of existing ones, and WuXi AppTec was among them 45. Because 1260H listing is the automatic route into BIOSECURE, the addition put the company on the statute's fast track the moment the list was published 3.

WuXi AppTec rejected the designation in the strongest terms. The company said it is not a Chinese military company and does not belong on the list, called the designation erroneous and unsupported by the facts or the legal criteria, and on 11 June filed suit against the Department of Defense in the United States District Court for the District of Columbia 6. On 7 August the court granted a preliminary injunction, relieving the company from the immediate consequences of the designation while the case proceeds 6.

A preliminary injunction is not a verdict. The merits are undecided, the order reportedly leaves the department free to redesignate, and appeals remain possible. More importantly for BIOSECURE, the statute's second route — designation by the Office of Management and Budget under its own criteria — does not depend on the 1260H list at all, and remains available regardless of how the court case ends 7.

Why peptides are in the middle of it

Peptides were not the reason the law was written; genomics and data security were closer to its origins. They are nevertheless one of the places where its effects concentrate, because contract peptide manufacturing has become one of the fastest-growing businesses in the region the law targets. WuXi AppTec reports its peptide and oligonucleotide work under a unit it calls TIDES. In its 2025 results the company said TIDES revenue had grown 96 per cent year on year, that it had finished building new peptide capacity at Taixing ahead of schedule, and that its total solid-phase synthesiser reactor volume had passed 100,000 litres 8. That is capacity built for a market in which demand for metabolic peptide drugs has outrun almost every forecast.

Peptide programmes are also unusually sticky. A validated manufacturing process is not a recipe that can be emailed to another plant. It is a specific sequence of resins, reagents, purification conditions and analytical methods, proven on specific equipment and written into regulatory filings that name the site. Moving it means transferring the methods, running demonstration and validation batches at the new plant, showing the product is comparable, and filing the change with regulators — work that companies have warned publicly can take longer than planned.

Where the work would go

The statute names no winners. It creates a reason to diversify and leaves the market to decide where. Contract manufacturers in India, which already hold large numbers of American and European regulatory approvals for chemical drug ingredients, have been the most vocal in presenting themselves as the natural alternative, and European and Korean plants with peptide capacity have made similar pitches. Whether that capacity is sufficient, at the scale and price that Chinese plants reached over two decades, is an open question that the next few years will answer.

For the research-reagent trade the law is indirect. It does not regulate catalogue sales, research-use-only material or private laboratories paying their own bills. What it can do is rearrange the industrial base underneath them. The same plants serve regulated and unregulated customers, and when regulated programmes move, capacity, prices and lead times move with them, in directions that nobody can yet predict with confidence.

The factories are not moving back in any literal sense, not yet. What has moved is the calculation. A plant's location, which for thirty years was decided almost entirely by solvent, labour and waste, now carries a legal weight in some contracts, and every company with a validated peptide process in the affected plants has had to price the cost of moving it. That cost — the comparability protocols, the validation batches, the regulatory variations — is where the policy meets the chemistry, and it is a technical subject with its own long literature.